Evidence map›Paper›PMID 40454648›Full record

ArticleJournal of medicinal chemistry2025

Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.

Urban Košak, Nika Strašek Benedik, Damijan Knez, Simon Žakelj, Jurij Trontelj, Anja Pišlar, Selena Horvat, Aljoša Bolje, Neža Žnidaršič, Neža Grgurevič and 15 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Urban KošakFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Nika Strašek BenedikFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Damijan KnezFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.ORCID 0000-0001-9917-1384
Simon ŽakeljFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Jurij TronteljFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Anja PišlarFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Selena HorvatFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Aljoša BoljeFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Neža ŽnidaršičInstitute of Preclinical Sciences, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, 1000 Ljubljana, Slovenia.
Neža GrgurevičInstitute of Preclinical Sciences, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, 1000 Ljubljana, Slovenia.
Tanja ŠvaraInstitute of Pathology, Wild Animals, Fish and Bees, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, 1000 Ljubljana, Slovenia.
Jakob KljunFaculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia.
Anna Skrzypczak-WierciochUniversity Centre of Veterinary Medicine JU-UA, University of Agriculture in Krakow, 24/28 Mickiewicza St., 30-059 Krakow, Poland.
Bingbing LvSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
Yucheng XiongSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
Qinjie WangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
Rui BianSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
Jikuan ShaoSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
José DiasDépartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91220 Brétigny sur Orge, France.ORCID 0000-0002-7625-0618
Florian NachonDépartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91220 Brétigny sur Orge, France.ORCID 0000-0003-0293-2429
Xavier BrazzolottoDépartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91220 Brétigny sur Orge, France.
Jure StojanInstitute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Haopeng SunSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.ORCID 0000-0002-5109-0304
Kinga SałatFaculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland.
Stanislav GobecFaculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.ORCID 0000-0002-9678-3083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Butyrylcholinesterase (BChE) is a promising drug target for alleviating the symptoms of canine cognitive dysfunction (CCD) and Alzheimer's disease (AD). We have recently developed lead compound

Indexed as

Alzheimer DiseaseButyrylcholinesteraseCholinesterase InhibitorsSulfonamidesAmyloid beta-PeptidesAnimalsBrainDogsHumansMaleMiceNaphthalenesPiperidinesScopolamineStructure-Activity RelationshipAmyloid beta-PeptidesButyrylcholinesteraseCholinesterase InhibitorsNaphthalenesPiperidinesScopolamineSulfonamides

Identifiers

PMID40454648
PMCPMC12169612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.